Podcasts about breakthroughs

MFJJ and Tim Connor sit down to chat about many things including: some recent archery breakthroughs for Tim, different shooting styles that are effective, and other ramblings. #archery #podcast Josh's Website, save 10% discount code "timc" https://www.podiumarcher.com/ Our Favorite E-Scouting Course save 20% discount code "joshandtim" https://bit.ly/4lxiV1Y Watch The Podcast on YouTube: https://www.youtube.com/@joshandtim Tim's YouTube Channel: https://www.youtube.com/@TimConnor13 Josh's YouTube Channel: https://www.youtube.com/@podiumarcher3447 Follow The Guys on Instagram:  https://www.instagram.com/podiumarcher/ https://www.instagram.com/_timconnor/

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Learn more about Dr. Michael Levin and his work: ⁠https://drmichaellevin.org/⁠ ⁠https://thoughtforms.life/⁠ ⁠https://www.youtube.com/@drmichaellevin/playlists⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Empowering Lives: Autism, Mental Health, and Healing with Dr. Cochrane In this episode Dr. Cochrane, a renowned psychologist with over three decades of experience. Together, they explore the challenges and strategies for addressing issues faced by neurodivergent individuals and those suffering from trauma. Dr. Cochrane shares her compassionate approach to cognitive behavioral therapy, the importance of self-regulation, and the power of gratitude practice. Through vivid examples, she illustrates the profound impact of vigilant parenting, therapy, and the critical distinction between feelings and facts. This powerful conversation underscores the importance of seeking help and fostering a profound understanding of autism and mental health. Meet Dr. Cochrane: A Renowned Psychologist Understanding Neurodivergence and Therapy Addressing Trauma and Emotional Regulation The Role of Coaching and Therapy Dealing with Psychosis and Severe Mental Health Issues Navigating Relationships and Communication Supporting Children and Teens The Power of Gratitude and Positive Mindset Conclusion and Final Thoughts INTRO/OUTRO: T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, I break down the six developments I'm watching in longevity for 2026 and why I believe we're closer than ever to cracking the code on aging. I explain how AI is already transforming personalized medicine (and how to prompt it for better results), introduce the Longevity Wingman app we're building to remove all friction from your health journey, and discuss why genetic testing is finally becoming truly actionable. I also cover the sequencing strategy behind regenerative procedures that most clinics get wrong, why nervous system optimization and shadow work may be the most underrated lever in longevity, and how quantum computing will change biology forever. If you stay for the last one, you'll understand why I think we're the luckiest generation of all time.   For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !  Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Takeaways ·       AI is becoming an integral part of health management. ·       The Longevity Wingman app aims to streamline health journeys. ·       Genetic testing is evolving to provide more actionable insights. ·       Optimizing regenerative procedures can significantly improve outcomes. ·       Understanding the nervous system is crucial for longevity. ·       Quantum computing may revolutionize biological analysis. ·       Personalized health strategies will become more accessible. ·       The integration of technology will reduce friction in health management. ·       Longevity practices are becoming more data-driven and customized. ·       The future of health looks promising with emerging technologies.     Chapters 00:00 We're about to crack the code on aging... 00:18 AI is building custom supplement stacks for individual patients now... 02:57 An app that removes every friction point from your longevity journey... 05:22 Your genes aren't your destiny... they're just tendencies you can manipulate... 06:56 Most regenerative procedures only get 40% of their potential results... 09:24 All of life comes down to one thing... your nervous system... 09:59 If you don't identify what's in the shadow you'll call your life fate... 13:25 Quantum computing will test millions of biological solutions simultaneously... 14:55 We're the luckiest generation of all time...   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Go to helixsleep.com/breakdown for 27% off sitewide. For an exclusive offer, go to https://bioptimizers.com/breaker and use my exclusive code BREAKER for 15% off. If you're struggling with OCD or unrelenting intrusive thoughts, NOCD can help. Book a free 15 minute call to get started: https://learn.nocd.com/BREAK Get 15% off OneSkin with the code BREAK at https://www.oneskin.co/BREAK #oneskinpod Head to Superpower.com and use code BREAK at checkout for $20 off your membership. Live up to your 100-Year potential. #superpowerpod Learn more about Dr. Michael Levin and his work: https://drmichaellevin.org/ https://thoughtforms.life/ https://www.youtube.com/@drmichaellevin/playlists Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us this week as Pastor John takes us through Nehemiah chapter 8. __ "Breakthroughs" Nehemiah 8:1-12 A picture of a breakthrough can empower us to pursue a burden. 1. Breakthroughs have no limits. - Breakthroughs aren't limited to certain people, past, or place. - “The remnant there in the province who had survived the exile is in great trouble and shame….” (Neh. 1:3). - precincts of the temple, so that none might be barred from attending…” They made space for a breakthrough to take place. 2. Breakthroughs happen through a hunger for God's Word. Jer. 15:16, Your words were found, and I ate them, and your words became to me a joy and the delight of my heart, for I am called by your name, O Lord, God of hosts. Ezekiel 3:2-3 2 So I opened my mouth, and he gave me this scroll to eat. 3 And he said to me, “Son of man, feed your belly with this scroll that I give you and fill your stomach with it.” Then I ate it, and it was in my mouth as sweet as honey. when he ate the Word and it became sweet as honey. 3. Breakthroughs heighten by the joy of the Lord - 2 looking to Jesus, the founder and perfecter of our faith, who for the joy that was set before him endured the cross, despising the shame, and is seated at the right hand of the throne of God. (Heb. 12:2)

In a world where technology is advancing faster than many people can comprehend, anxiety and uncertainty are becoming part of the human experience. Breakthroughs in generative AI, biotechnology, and other emerging technologies are transforming how we live, work, and govern ourselves faster than institutions and individuals can adapt.In this episode, global ethics expert Dr. Andrea Bonime-Blanc explores the human side of this technological acceleration. She discusses why the rapid rise of artificial intelligence is creating widespread unease, how the nature of work is likely to shift as intelligent machines become more capable, and what leaders should be doing now to prepare their people and organizations for a radically different future.Andrea also addresses how technologies should be governed when they are evolving much faster than regulation can keep up. From corporate boardrooms to national governments to global institutions, she explains the complex challenges of building ethical frameworks that allow innovation to flourish while protecting society from unintended harm.The conversation finishes with Andrea's thoughts on how the same technologies that provoke fear could help solve some of humanity's most difficult challenges, from healthcare breakthroughs to climate solutions. She shares what gives her hope and she provides advices for how leaders, organizations, and citizens can help ensure that powerful new technologies ultimately serve the human condition rather than undermine it.Andrea Bonime-Blanc, JD/PhD, is founder and CEO of GEC Risk Advisory, a board member, strategic advisor, and multiple book author. She specializes in the governance of change focusing on global strategic risk, leadership trust, geopolitical change, sustainability, cyber resilience, and exponential tech, advising business, NGOs, and government. Her latest book is “Governing Pandora: Leading in the Age of AI and Exponential Technology.”

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Tait Fletcher on Jiu-Jitsu, Truth, Persistence, and Healing Pete Deeley interviews Professor Tait Fletcher about how combat sports shaped his life and character. Fletcher traces his path from Dog Brothers stick fighting to early Jiu Jitsu training in the 1990s, learning from figures including Arlan Sanford, Amal Easton, later also receiving a black belt from Eddie Bravo. He describes competing widely, fighting in MMA, training with notable fighters, and appearing on The Ultimate Fighter Season 3, emphasizing Eddie Bravo's systematic coaching. The conversation focuses on jiu-jitsu as a source of truth, humility, community, and accelerated learning, stating that teammates improve together through generosity rather than ego. Fletcher discusses plateaus, staying the course, finding joy in training, and how a severe head injury in 2019 led him to rely on Jiu Jitsu, discipline, curiosity, and community to recover and re-engage with life, advocating responsibility, eliminating complaints, and consistent action toward one's destiny. 00:00 Welcome and Introduction 00:50 Why Combat Sports 02:04 Dog Brothers to Groundwork 03:54 Early BJJ and First Coaches 05:08 Competition and Breakthroughs 06:16 Black Belts and LA Move 09:55 Jiu Jitsu Shaves Time 11:02 Truth and Gym Culture 15:57 Ego Checks and Mentors 25:09 Injury Recovery and Resilience 28:24 Curiosity and Healing Forward 30:45 Act Reflect Repeat 32:04 Life Is A Beta Test 32:26 Jiu Jitsu Finds The Path 33:02 The Artist Roadmap 35:32 Create For Yourself 36:37 Stay Ready For Opportunity 37:42 Curiosity Meets Faith 40:16 Suffer Well In Training 44:37 Resist Complaining 47:18 Move A Muscle 49:02 Everyone Is An Artist 53:20 Jiu Jitsu And Presence 55:29 Grandparent Presence Lessons 01:00:46 Gratitude And Goodbye

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

Today's episode is a special one as we celebrate the 500th episode of the show and over 11 million downloads worldwide. I'm joined by Jess Giacobbe from my team, who turns the microphone around and asks me the questions listeners have always wanted to ask about my journey, my work, and what I've learned along the way. We talk about how this podcast began, the real behind-the-scenes moments that challenged me, the times I almost quit, and how learning to trust my intuition changed everything. I also share what "downloads" actually feel like, how triggers reveal unconscious beliefs, and why real change can happen faster than you think when you shift your response. *Congratulations to the winners of our 500th Episode Giveaway - Heather R. & Joellen G. Thank you to everyone who shared the podcast or left a review!* In this episode, you'll learn:  How the podcast began and why I almost didn't start it What intuition and "downloads" actually feel like in real life The biggest lessons I learned from setbacks and rebuilding my business Why triggers reveal old beliefs and how to use them for growth How to stay grounded in your Adult Chair even during life's hardest moments Resources from this Episode: Get your free trigger kit here! In case you haven't already, get your copy of The Adult Chair book now MORE MICHELLE CHALFANT Website: https://www.michellechalfant.com Membership: The Adult Chair Collective https://www.michellechalfant.com/collective  Instagram: https://www.instagram.com/themichellechalfant Facebook: https://www.facebook.com/TheMichelleChalfant The Adult Chair® Facebook Group: https://www.facebook.com/groups/theadultchair YouTube: https://www.youtube.com/c/Michellechalfant

Brought to you by TogetherLetters & Edgewise!In this episode: Several Meta employees have started calling themselves 'AI builders'Lovable-hosted app littered with basic flaws exposed 18K users, researcher claimsForget solid-state batteries – researchers have made a lithium-ion breakthrough that could boost range and drastically lower costsUber acquiring parking app SpotHero as it moves beyond ride-hailing and food deliveryHow a doomsday AI blog post wiped out billionsThis App Warns You if Someone Is Wearing Smart Glasses NearbyHands on: I'm super impressed with the Galaxy S26 Ultra's new Privacy DisplayTesla touts California robotaxis but does nothing to get permitsFedEx will refund customers for Trump's tariffs — if there ever are any refundsAndroid's Find Hub adds iPhone-like luggage tracking linksAnother Oracle outage is messing up US TikTokTech Rec:Sanjay - TogetherLettersAdam - Wisper FlowFind us here:sanjayparekh.com & adamjwalker.comTech Talk Y'all is a proud production of Edgewise.Media.

Welcome to Resiliency Radio with Dr. Jill Carnahan, where today's episode challenges decades of conventional thinking about Restless Legs Syndrome (RLS). Dr. Jill is joined by Dr. James C. Anderson, whose groundbreaking research suggests that RLS may not be primarily a dopamine disorder—but instead, a problem of mechanical nerve compression in the lower leg. In this fascinating and science-driven discussion, Dr. Jill Carnahan and Dr. Anderson explore how decompression of the common fibular, superficial fibular, and tibial nerves may significantly reduce symptoms like burning, tingling, cramping, creeping sensations, and sleep disruption. This episode offers hope to patients who have failed dopaminergic medications and provides clinicians with deeper mechanistic insight into the root causes of RLS and peripheral neuropathy. ✨ Like, subscribe, and share to help more people discover innovative, root-cause solutions for chronic restless legs and sleep disruption.

Need help? Check out these resources: www.firstresponderwellness.co/resources or Dial 988 for immediate help.    Marriage, Badges, and Breakthroughs    In this conversation, Conrad sits down with Dylan and Kella Bates—two first responders who've worked in very different worlds, from the nonstop pace of the DC area to the isolation and intensity of rural Alaska. They talk candidly about what the public doesn't see: the whiplash of going from an infant death to a “noise complaint,” the personal weight of responding to one of your own in crisis, and how lack of debriefing and ongoing training can quietly erode an officer's wellness over time. They also open up about marriage inside the first responder life—how “investigative mode” can follow you home, why trust and communication have to be intentional, and why friendships outside the job can be the thing that keeps you grounded. The episode closes with the practical work they're doing now through their peer support community, the Blonde in Blue Network—creating a space where first responders (and families) can show up honestly, without fear of it coming back to their department. Join the Support Group: https://www.patreon.com/badgesandbreakthroughs   +++++   FIRST RESPONDER WELLNESS PODCAST Order the PTSD911 Film and Educational Toolkit here: https://ptsd911movie.com/toolkit/ Web site:  https://ptsd911movie.com/ Instagram: https://www.instagram.com/ptsd911movie/ Facebook: https://www.facebook.com/ptsd911movie/ YouTube: https://www.youtube.com/channel/UClQ8jxjxYqHgFQixBK4Bl0Q Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/first-responder-wellness-podcast/id1535675703 Listen on Spotify: https://open.spotify.com/show/2wW72dLZOKkO1QYUPzL2ih Purchase the PTSD911 film for your public safety agency or organization: https://ptsd911movie.com/toolkit/ The First Responder Wellness Podcast is a production of First Responder Wellness Solutions, LLC Copyright ©2026 First Responder Wellness Solutions, LLC - All rights Reserved.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the pharmaceutical and biotech industries. The landscape continues to evolve with scientific breakthroughs, regulatory hurdles, and strategic alliances that have profound implications for drug development and patient care.Let's begin with Novo Nordisk's substantial investment of $500 million into an Ireland-based plant. This move reflects the ongoing demand for obesity treatments like Wegovy, a GLP-1 receptor agonist known for its efficacy in diabetes and weight management. The expansion aims to enhance production capabilities, particularly for markets outside the US, highlighting the global demand for such therapies. Recent studies in rodents suggest that GLP-1 medications may also support heart attack recovery by relaxing blood vessels, indicating broader cardiovascular benefits. This illustrates the multifaceted potential of GLP-1 receptor agonists beyond their primary indications.Turning to regulatory developments, the FDA has issued complete response letters to AstraZeneca and GSK, citing deficiencies in their data submissions. The feedback questions the data integrity of AstraZeneca's Saphnelo and the efficacy of GSK's Exdensur. These letters emphasize the importance of robust clinical evidence for achieving regulatory approval, underscoring the FDA's stringent standards. Such regulatory scrutiny highlights the necessity for pharmaceutical companies to ensure comprehensive and transparent data presentation.In strategic maneuvers within the industry, Esperion Therapeutics has acquired Corstasis Therapeutics for over $75 million, bringing the newly FDA-approved nasal spray Enbumyst into its portfolio. This acquisition illustrates ongoing consolidation trends aimed at diversifying product offerings and strengthening market positions in an increasingly competitive landscape.Meanwhile, DISC Medicine's decision to lay off 20% of its workforce following the FDA's rejection of a rare disease drug candidate underscores the volatility and risk inherent in drug development. This highlights the financial and operational challenges biotechs face when navigating complex regulatory pathways.Novo Nordisk and BioMarin have received FDA label expansions, allowing them to reach broader patient populations or offer additional therapeutic indications. Such expansions are crucial for enhancing treatment access and driving company growth. However, these advancements also reflect the challenges companies face in meeting evolving regulatory expectations while striving to expand their market footprint.Geopolitical tensions impact the industry as well, with companies closely monitoring employee safety and supply chain stability amid conflicts in regions like the Middle East. This situation highlights the vulnerabilities of global operations and underscores the need for robust contingency planning to maintain medicine access during crises.On the innovation front, Kyowa Kirin has discontinued its late-stage autoimmune disease program following cancer concerns linked to its anti-OX40 monoclonal antibody. This decision reflects the complexities of balancing innovative research with patient safety considerations. The discontinuation followed new cancer cases among participants receiving an anti-OX40 monoclonal antibody treatment, emphasizing the critical need for robust safety monitoring throughout the development process.Theravance Biopharma's substantial downsizing reflects similar challenges after a failed phase 3 trial for a blood pressure disorder drug led to significant corporate restructuring. This highlights how clinical setbacks can profoundly impact corporate strategy and employee livelihoods, serving as cautionary tales about resource investments required inSupport the show

Leena Dattani, FCMA, CGMA, discusses how limiting beliefs affected her professional growth, the small steps she takes to overcome them, and the realisation that changed her idea of what it means to be a leader.  "I had a vision that in order to be a great leader, you have to be loud," Dattani said. "I think because I felt that that needed to be the case, I was almost imitating what I thought a leader should be rather than being myself." Dattani also discusses how one organisation achieved the buy-in to improve gender equity, some ways women can start to back themselves professionally, and what International Women's Day means to her.  What you'll learn from this episode: Small steps for overcoming poor self-confidence. The importance of building a supportive network. One realisation that helped Dattani become her own leader. How one organisation created a business case for gender equity. One trick for challenging limiting beliefs. What International Women's Day means for Dattani.

Episode 01: We are SOOOO Back! After a year-long hiatus, The Real & Raw Show is officially back in the studio! In this season premiere, John Marrone gets candid about why he stepped away, the reality of content burnout, and what it actually takes to find joy in your work again. Whether you've been here since 2018 or you're just joining the family, this episode is a reminder that growth often requires a reset. John shares updates on his latest ventures—from real estate mastery to the launch of Shore Sips—and lays out the vision for a season focused on real events, real tactics, and real change. Inside this episode: The "Job" vs. The "Passion": Why John took a break to stop "forcing" content. Business Updates: Life as an entrepreneur, from coaching to the beverage industry. The Audience of One: Why the best content starts with being purposeful for yourself first. What's Next: A look at the guest list and topics coming your way in 2026. Connect with John: Real Estate Mastery Coaching: https://gorealestatemastery.com/register-sales YouTube: https://www.youtube.com/@JohnMarrone Instagram: https://www.instagram.com/realjohnmarrone/ Don't forget to Like, Subscribe, and leave a Review if you're ready to kick the door down this year!

EPISODE SUMMARY What if we could predict whether a drug will work for a specific person before they ever take it? In this episode, Claudia Garbutt interviews Israeli neuroscientist and biotech entrepreneur Dr. Nisim Perets, founder of Itay&Beyond — a company pioneering patient-derived brain organoids on a chip to accelerate precision medicine for neurological and psychiatric conditions like Autism Spectrum Disorder and epilepsy. Dr. Perets and his team are growing miniature brain tissues from a patient's own cells, placing them on a chip, and measuring their electrical activity to predict how that specific brain might respond to medication. Yes — really. Mini Brains. Massive Breakthroughs.   We talked about... Using lab-grown brain tissue to predict drug responses Neuroscience, nanoparticles & synthetic biology Precision medicine for autism, epilepsy, and psychiatric disorders EPISODE NOTES Dr. Nisim Perets is an Israeli neuroscientist and biotech entrepreneur specializing in drug development, targeted delivery systems, and advanced neurotechnologies. His work focuses on translating cutting-edge neuroscience into real-world therapeutic solutions, including patient-derived lab-grown brain tissues on a chip. Dr. Perets has published multiple high-impact scientific papers and is the inventor of more than ten medical patents. He was part of the scientific founding team of NurExone Biologic (NRX), a company developing nanoparticle-based therapies designed to promote recovery after severe spinal cord injuries. In 2021, he founded Itay&Beyond, a biotechnology company pioneering personalized brain-on-a-chip platforms. The company develops patient-derived lab-grown brain tissues (Organoids) to predict drug efficacy for neurological and psychiatric conditions before clinical use, including Autism Spectrum Disorder and epilepsy, aiming to transform precision medicine in the brain sciences. The company is named after the son of one of the founders, Itay, a young man with low-functioning Autism Spectrum Disorders   Links: https://itayandbeyond.com/ https://www.linkedin.com/in/nisimperets/   --------- Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess ------------------ Music credit: Vittoro by Blue Dot Sessions (www.sessions.blue) ----------------- Disclaimer: Podcast Episodes might contain sponsored content.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic, from medical breakthroughs to lifestyle impacts.Johns Hopkins Bloomberg School of Public Health researchers analyzed 64 clinical trials with tens of thousands of patients on GLP-1 drugs like semaglutide, the key ingredient in Ozempic. They found these drugs work similarly across ages, races, ethnicities, starting weights, and blood sugar levels. Women saw about 11 percent average weight loss from their starting weight, while men averaged 7 percent, a meaningful difference possibly linked to estrogen interactions. Senior author Hemal Mehta says this builds confidence for doctors and patients in diverse groups. The study appeared in JAMA Internal Medicine on March 2.In exciting pill news, ScienceAlert reports a phase 3 trial where Eli Lillys orforglipron outperformed oral semaglutide. Among 1,698 people with type 2 diabetes, orforglipron delivered 6 to 8 percent weight loss and better blood sugar control versus 4 to 5 percent on semaglutide tablets. It does not need an empty stomach, boosting convenience, though more dropped out due to stomach issues. Published in The Lancet, this positions orforglipron as a strong oral contender, with heart health trials underway.J.P. Morgan Global Research forecasts the GLP-1 market hitting 200 billion dollars by 2030, with 25 million Americans on these treatments, up from 10 million in 2025. Oral versions approved late 2025 are driving growth by skipping injections. Medicare and Medicaid expansions, like the BALANCE program capping out-of-pocket at 50 dollars monthly, plus falling prices and generics abroad, mean broader access. This could reshape food spending, cutting grocery bills as calorie intake drops.Patient satisfaction with semaglutide remains high, Rheumatology Advisor notes, fueled by strong weight loss outweighing gut side effects.These updates show Ozempic and kin transforming health, but talk to your doctor for personal fit.Thanks for tuning in, listeners. Subscribe for more insights. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode, we explore the complex world of degenerative and inflammatory conditions, and how stem cell–derived exosomes may offer a new frontier in regenerative care. Joining us to share his perspective is Caleb Granger, the Founder and President of Apex Medical – a cutting-edge provider focused on advanced biologic therapies. Apex Medical harnesses high-concentration, clinical-grade stem cell exosomes, which are tiny extracellular vesicles released by stem cells. These vesicles carry proteins, lipids, and genetic material that help cells communicate and promote tissue repair. With growing interest in their potential to modulate inflammation and support tissue regeneration, could exosomes represent a major shift in how we approach chronic disease, joint degeneration, and neurologic decline? Caleb sits down to explain… Hit play to learn more about: The two pillars of Apex Medical's regenerative approach. How stem cell exosomes differ from stem cell therapy. The ways in which exosomes are introduced into the body. The intersection of biohacking, longevity, and regenerative medicine. Before founding Apex Medical, Caleb held senior leadership roles in the spine and orthopedic industries, overseeing marketing, sales, and product strategy at NuVasive and SeaSpine. His experience includes product development and earned recognition for top sales performance, which has fueled his mission to bring innovative regenerative medicine to patients. Follow Caleb on Instagram: @calebgrangerofficial Follow Apex Medical on Instagram: @apexregenerative

SpaceTime with Stuart Gary Gary - Series 29 Episode 26In this episode of SpaceTime, we delve into NASA's postponed return to the lunar surface, a remarkable hypersonic test flight by an Australian company, and the fascinating hidden chemistry at the heart of the Milky Way galaxy.Nasa's Lunar Return DelayedNASA has announced a significant delay in its plans to return humans to the lunar surface, pushing the Artemis 4 mission to 2028. The upcoming Artemis 3 mission will focus on testing systems in low Earth orbit instead of conducting a lunar landing. NASA officials emphasize the need for a methodical approach to ensure the safety and success of future missions, including critical tests of lunar landers from SpaceX and Blue Origin. This strategic shift aims to facilitate at least one major lunar landing annually starting in 2028.Successful Hypersonic Test FlightAn Australian scramjet has achieved a successful test flight, propelling the Dart hypersonic aircraft to speeds exceeding five times the speed of sound. This milestone underscores the potential of scramjet technology, which utilizes a unique engine design without moving parts to achieve hypersonic speeds. The successful mission, launched from Rocket Lab's Wallops Island facility, marks a significant step toward developing autonomous hypersonic vehicles capable of sustained flight and could pave the way for future space travel advancements.Revealing the Milky Justin's ChemistryAstronomers have captured the largest and most detailed image of the central region of the Milky Way galaxy, unveiling a complex network of filaments and cosmic gas. This groundbreaking observation, made possible by the Atacama Large Millimeter/submillimeter Array (ALMA), provides unprecedented insights into the processes of star formation in the galactic center. The study reveals the intricate chemistry of the central molecular zone, detecting various molecules and enhancing our understanding of star formation in extreme environments.www.spacetimewithstuartgary.com✍️ Episode ReferencesScientific Reports, Monthly Notices of the Royal Astronomical SocietySupport our podcast: Become a supporter.

This episode explores how sustained scientific ambition, backed by flexible philanthropy, has helped transform HIV from a fatal diagnosis into a manageable condition and why the search for a cure remains both urgent and achievable. At the centre of the conversation is the work of amfAR and its distinctive role in advancing research that changes lives far beyond a single disease area. Founded in the mid-1980s, at a time when HIV and AIDS were poorly understood and highly stigmatised, the organisation emerged from the determination of clinicians, researchers and advocates who refused to wait for slow-moving systems to respond. From the outset, the mission was clear: fund innovative research quickly, support bold ideas early, and accelerate scientific discovery where it was needed most. Since its first grants in 1985, the organisation has invested nearly one billion dollars in research and supported more than 3,900 researchers across the world. Rather than simply awarding grants, its approach has been to invest in people and ideas, often at the earliest and riskiest stages. Many of those early investments have gone on to underpin treatments now used globally, including antiretroviral therapies that allow people living with HIV to lead long, healthy lives. The episode places this progress in today's global context. More than 40 million people worldwide are living with HIV, with around 1.3 million new infections each year. While treatment has transformed outcomes in many countries, access remains deeply unequal. Women and girls account for over half of those living with HIV globally, and people in low-income and marginalised communities, particularly in sub-Saharan Africa, continue to face life-threatening barriers to care. Against this backdrop, the case for a cure remains compelling. Lifelong treatment depends on stable health systems, consistent access and freedom from stigma, conditions that are far from guaranteed. A cure would remove these structural vulnerabilities. Importantly, the science now points to possibility. Around ten individuals have been effectively cured of HIV, providing researchers with vital clues and a credible roadmap. Current cure-focused research is tackling some of the most complex questions in virology. This includes understanding latent viral reservoirs, where HIV hides in the body, and finding ways to reactivate and eliminate the virus. Researchers are also studying elite controllers, people whose immune systems suppress HIV without medication, to uncover mechanisms that could inform new treatments. Alongside this, insights from cancer, ageing, autoimmune disease and other viral infections are increasingly shaping HIV research, highlighting the interconnected nature of scientific discovery. A key theme running through the conversation is what defines a viable cure. It must be scalable, affordable and easy to administer, not a solution that only works in specialist settings. This emphasis on real-world applicability shapes funding decisions and research priorities. The funding model itself is central to this work. Research is supported entirely through private philanthropy, from individual donors and family foundations to global fundraising events. Independence allows decisions to be driven by science rather than politics, while short funding timelines enable researchers to move quickly. Rigorous peer review ensures standards remain as high as those of major public institutions, without the inertia that can stifle innovation. Beyond HIV, the episode highlights how this model has influenced advances in other fields. Research originally funded to understand HIV has contributed to breakthroughs in cancer immunotherapy and vaccine development, including technologies later used in mRNA vaccines. Today, the organisation is expanding its focus to areas such as cancer, Alzheimer's disease, immunotherapy and artificial intelligence, particularly where these intersect with the needs of an ageing HIV-positive population. Woven throughout the discussion is the human impact of research. Funding science does more than produce data and treatments; it provides hope. Knowing that researchers are actively working towards a cure can fundamentally change how people live with a diagnosis. Investment in early-stage research becomes an investment in dignity, longevity and possibility. The episode closes with a clear message. Scientific discovery is not confined to governments or large institutions. Individuals and philanthropists can play a decisive role in advancing research that affects every household. Supporting bold ideas early is one of the most powerful ways to accelerate global health progress and, ultimately, to help make AIDS history. Visit our Knowledge Hub at Lidji.org for information on 350+ case studies and interviews with remarkable leaders in philanthropy, sustainability and social entrepreneurship. 

Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a professor at the Oklahoma Medical Research Foundation, explains why physiology remains central to biomedical innovation. Bodine details how physiology strengthens biotech and pharmaceutical research by clarifying how therapies behave in complex biological systems, identifying unintended effects and supporting stronger regulatory narratives. She also examines the expanding role of physiology in wearable technology, remote patient monitoring and artificial intelligence, where biological context is essential to turning large data sets into clinically meaningful insights. The episode also highlights the society’s campaign, “Physiology: The Science Life Depends On,” aimed at elevating awareness of foundational science amid funding uncertainty. For executives, investors and health care leaders seeking sustainable innovation and patient impact, this discussion underscores a clear message: Breakthroughs depend on physiology. Listen to the full interview.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

3 Major Breakthroughs I Learned After 13 Years of Cold Calling

The Importance of Integrity | Burdens to Breakthroughs | Nehemiah 5-7 by CityLight Church

High Timeline Living Website:https://www.hightimelineliving.com/Readings with Kristinhttps://kristiraeastrology.wixsite.com/blogFun Astrology YouTube Channel:https://www.youtube.com/@funastrologypodcastBuy Thomas a Coffee!https://www.buymeacoffee.com/funastrologyThank you!Join the Fun Astrology Lucky Stars Club Here!Old Soul / New Soul Podcast - Back Episodes:https://www.buzzsprout.com/2190199https://www.youtube.com/@OldSoulNewSoulAstrologyPodcast

We rethink success by shifting focus from loud breakthroughs to the quiet power of micro shifts that build identity, resilience, and momentum. From a Bad Bunny halftime insight to cold plunges, treadmills, and seed-sowing, we map a path of small, daily actions that compound into lasting change.• why chasing loud breakthroughs burns us out• the hundred-pound stone and unseen repetitions• belief, energy, and the Bad Bunny halftime moment• micro shifts as micro identities that stack• cold plunge lessons and nervous system rewiring• avoiding adjustment shock with gradual training• cause and effect: inputs first, outcomes later• invisible work that prepares visible results• proof through small wins and compounding effort• choosing one uncomfortable action each day• pain as the prompt for personal and social change✨ Ready to take your growth to the next level? ✨The DG Mindset Academy | School of Growth is now open! Inside, you'll get access to my masterclasses, live 8-week courses, and Q&A coaching calls with me — all in a semester-style framework designed to help you transform at your own pace. Click here to join the Academy Your next level of growth starts now.

Hello Beautiful, I'm so grateful you're here with me.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show

This week we're in hygge mode, uncovering traumas in our generational home with the host of This Had Oscar Buzz, Joe Reid! One of the breakout Oscar films of the year is Joachim Trier's Sentimental Value, a warm, realist Norwegian film about a difficult but brilliant director (Stellan Skarsgard), his two daughters (Renate Reinsve and Inga Ibsdotter Lilleaas), and an American actress cast in the auteur's new film (Elle Fanning). All four performances earned Oscar nominations, along with nominations for Best Picture, Best International Feature, Best Film Editing, and Best Original Screenplay. Sentimental Value also highlights a recurring phenomenon in Hollywood, wherein the Academy will pass over a director's breakout film but shower the follow-up with nominations. In Trier's case, his previous film The Worst Person in the World received nominations for Best International Film and Original Screenplay but, in our opinion, deserved many more. We try to break down how and why this happens, whether films about filmmaking have an innate appeal to Oscar voters, how Fanning's star power helps bridge the international gap for voters, and the film itself, including its deft intermingling of artistic expression and sublimated generational trauma.  With Joe's guidance, we also check in on some of the Oscar-buzziest films of the year that didn't pan out, check in on the state of the acting category race and some potential upsets, and celebrate The Secret Agent's breakout star Tânia Maria and her new role as Burger King spokeswoman. Sign up for Check Book, the Blank Check newsletter featuring even more “real nerdy shit” to feed your pop culture obsession. Dossier excerpts, film biz AND burger reports, and even more exclusive content you won't want to miss out on. Join our Patreon for franchise commentaries and bonus episodes. Follow us @blankcheckpod on Twitter, Instagram, Threads and Facebook!  Buy some real nerdy merch Connect with other Blankies on our Reddit or Discord For anything else, check out BlankCheckPod.com Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

This year’s Academy Awards will include the first-ever Oscar for Achievement in Casting. It’s the first new category in 25 years, since Best Animated Feature was added in 2001 (which inaugural award was won by Shrek). Casting, though, is seen as kind of an illusive, inscrutable art form. We feel like we can separate out the writing and the editing and the costuming and the directing from a thing. But the cast kind of IS the thing a lot of the time, right? It’s kind of inextricable from the thing, it feels like. This hour: a look at the art of casting. GUESTS: Mellini Kantayya: An actor and writer and the author of Actor. Writer. Whatever. (essays on my rise to the top of the bottom of the entertainment industry) John Frank Levey: A four-time Emmy Award-winning casting director and the author of Right for the Role: Breakdowns, Breakups and Breakthroughs from 35 Years of Casting Iconic TV Shows Connor Ratliff: An actor, writer, and comedian and the creator and host of Dead Eyes Michael Schulman: A staff writer at The New Yorker and the author of Oscar Wars: A History of Hollywood in Gold, Sweat, and Tears Support the show: http://www.wnpr.org/donateSee omnystudio.com/listener for privacy information.

Stormy seas battered the hatches of the SS Sparks & Recreation as news of a shuffle bug hits the Realms! Join the crew as they talk through this surprising discovery and what it means for players.The storm doesn't stop there – more bug talk follows as the crew discusses the latest update before breaking down which balance changes actually landed.Finally, a breakthrough has been made on Hero Helper development, and Tuff brings the latest from behind the scenes. All that and more on this episode, thanks for listening! WWYD: 7:08Bugs: 21:34Balance: 46:59(Hero-helper) Breakthrough: 1:41:56Community Round-up: 1:47:15Taps, Scrap, and Good-byes: 2:04:10Hero Realms is a fantasy-themed expandable deckbuilding game from Wise Wizard Games.Hosts: Chris "DblDubz" Walberg, Cooper "Filtrophobe" Fitzpatrick, and John "Tuff" LabellaProducer: Chris WalbergHero Helper: https://hero-helper.com/Realms Rising: https://www.realmsrising.comYou can find the WWYD screenshots for this episode here: https://www.realmsrising.com/podcast/sparks-and-recreation-96-bugs-balance-and-breakthroughsPatreon: https://patreon.com/sparksandrecHyperGeometric Calculator: https://aetherhub.com/Apps/HyperGeometricCommunity Tournaments & Events Primer (+ signup links): https://www.realmsrising.com/community-events/Realms Rising Discord: https://discord.gg/8pTxKqzFDcContact S&R: contact@sparks-and-recreation.comSupport Sparks & Rec: https://hero-helper.com/support-usSparks & Recreation Website: https://www.realmsrising.com/sparks-and-recreation/Thank you so much to Level 12 Hero Sarah T., Warden Slayer, as well as Level 7 Hero Nudeltulpe!Specific songs used in this episode were:Intro/Outro Music: "Uplifting Orchestra Pack" by GoodBunny. (Under the Music Standard License)Licensed under Creative Commons BY Attribution 4.0 License Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

It's EV News Briefly for Tuesday 24 February 2026, everything you need to know in less than 5 minutes if you haven't got time for the full show.Patreon supporters fund this show, get the episodes ad free, as soon as they're ready and are part of the EV News Daily Community. You can be like them by clicking here: https://www.patreon.com/EVNewsDailyDALLAS SUPPLIER CLAIMS THREE-MINUTE LITHIUM-ION CHARGE https://evne.ws/3OuytZC DONUT LAB BATTERY TESTS HIT 11C CHARGING https://evne.ws/4qSEkW0 SLATE AUTO PICKUP SPOTTED CHARGING IN MICHIGAN https://evne.ws/4rzzgXN SAMSUNG SDI TARGETS LITHIUM-METAL BATTERY WEAK SPOT https://evne.ws/4qUkJEO KIA BRINGS PV5 ELECTRIC VAN TO CANADA https://evne.ws/3MLHNri ALLEGO CUTS UBER DRIVERS' DC CHARGING COSTS https://evne.ws/4kSUBst BMW TO DROP LEVEL 3 ON 7 SERIES https://evne.ws/46lma86 FORD PLANS 2026 PIKES PEAK MACH-E RETURN https://evne.ws/4kT1Qkf DENZA B8 BECOMES AUSTRALIA'S HEAVIEST PASSENGER SUV https://evne.ws/4s80QuT DIESEL TRUCKS AND BUSES COST AUSTRALIA A$6.2BN A YEAR https://evne.ws/3ZWPpdF PHOENIX CONTACT LAUNCHES 500 KW NACS, CCS CABLES https://evne.ws/4tOmFlb SOLAR PANELS BOOST SHEEP AND POWER NEAR DUBBO https://evne.ws/4rxDKxT

In this episode of Making Sense, Kate Finlayson, Global head of the FICC Market Structure and Liquidity Strategy, is joined by Sandy Kaul, Executive Vice President and Head of Innovation at Franklin Templeton, and Scott Lucas, head of Markets Digital Assets at J.P. Morgan. Together, they explore the rapid advancements in blockchain technology, and discussing what's changed, what's credible, and what institutional investors should be thinking about as market structure evolves. Sandy and Scott, who also serve as co-chairs of the CFTC's Digital Assets Subcommittee, share insights on blockchain adoption milestones, regulatory developments, the convergence of traditional and decentralized finance, and the future of interoperability and market infrastructure.   This episode was recorded on February 10, 2026.  The views expressed in this podcast may not necessarily reflect the views of JPMorgan Chase & Co, and its affiliates, together J.P. Morgan, and do not constitute research or recommendation advice or an offer or a solicitation to buy or sell any security or financial instrument. They are not issued by Research but are a solicitation under CFTC Rule 1.71. Referenced products and services in this podcast may not be suitable for you, and may not be available in all jurisdictions. J.P. Morgan may make markets and trade as principal in securities and other asset classes and financial products that may have been discussed. The FICC market structure publications, or to one, newsletters, mentioned in this podcast are available for J.P. Morgan clients. Please contact your J.P. Morgan sales representative should you wish to receive these. For additional disclaimers and regulatory disclosures, please visit www.jpmorgan.com/disclosures Copyright 2026 JPMorgan Chase & Company. All rights reserved.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

You might remember Alexandra Paul as one of the stars of Baywatch or the Tom Hanks-Dan Aykroyd Dragnet film. You may not have realized that as a child and on to her long trip through the worlds of modeling and Hollywood, she was bingeing and purging and dealing with severe eating disorders. She tells us about her relationship with sugar and what food meant emotionally. Then we're joined by Dr. Cynthia Bulik, one of the top experts on eating disorders in the world today, to talk about remarkable progress in understanding the genetic components of eating disorders. Rather than blame family (especially mothers), peer pressure, or fashion culture, Dr. Bulik says some people are much more prone to developing eating disorders due to the genes they happened to get. You can be part of her research by visiting EDGI2.org. Thank you to all our listeners who support the show as monthly members of Maximum Fun. Check out our I'm Glad You're Here and Depresh Mode merchandise at the brand new merch website MaxFunStore.com! Hey, remember, you're part of Depresh Mode and we want to hear what you want to hear about. What guests and issues would you like to have covered in a future episode? Write us at depreshmode@maximumfun.org. Depresh Mode is on BlueSky, Instagram, Substack, and you can join our Preshies Facebook group.  Help is available right away. The National Suicide Prevention Lifeline: 988 or 1-800-273-8255, 1-800-273-TALK Crisis Text Line: Text HOME to 741741. International suicide hotline numbers available here: https://www.opencounseling.com/suicide-hotlines  

Why do revolutionary ideas so often come from outsiders? Do good scientists sometimes crowd out great ones? Do we still have room for scientific cowboys? And what is the relationship between national security and modern science? Are scientists participants in a larger game they barely see? What if the most important ideas are the ones you’re not allowed to hear about? From Crick and Watson to nuclear bombs and AI, today we’ll cover it all with physicist, mathematician, and iconoclast Eric Weinstein.

Deterred but Determined | Burdens to Breakthroughs | Nehemiah 4 by CityLight Church

Pisces season is the pre-beginning of the zodiac year. It is the liminal space before Aries, when things are still forming, dissolving, clarifying, and choosing. In this episode, I walk through what Pisces season tends to stir up, and why this particular Pisces season matters in a bigger, longer arc.The headline is the Saturn–Neptune conjunction at 0° Aries (Feb 20). We have been building toward this since last summer. Neptune brings the dream, the vision, the imagination. Saturn brings the structure, the commitment, the foundation that makes something real. I talk about how I'm working with it in practice: writing it down, making a plan, building scaffolding, and taking tangible steps so the vision actually has somewhere to land.From there, we move into the rest of Pisces season's timeline: eclipse season, Mercury retrograde in Pisces, Mars entering Pisces, and the Virgo lunar eclipse that highlights the Pisces–Virgo polarity (oneness vs discernment, spirituality vs practicality, intuition vs the calendar). I close with the pivot point that changes the temperature entirely: March 20, the astrological new year, when the Sun enters Aries and Mercury stations direct, lighting up one of the most Aries-activated days I have ever seen on a chart.Episode timestamps00:00 Pisces Season Begins: Big Transits, Eclipses & the ‘Grand Finale' Energy00:48 What Pisces Really Means: Endings, Pre-Birth, Purpose & Interconnectedness03:11 Saturn–Neptune at 0° Aries: Turning Dreams Into Reality (How to Work With It)06:03 Practical Manifestation Tips: Lists, Plans, and Building Saturn Scaffolding09:10 Key Dates Kick Off: Mars–Chiron + Venus Trine Jupiter (Healing Meets Ease)12:36 Mercury Retrograde in Pisces: Shadow Clues, Re-words, and Water-Sign Caution14:58 Feb 27 Power Day: Mars Square Uranus + Sun Conj North Node + Mercury Conj Venus19:10 Mars Enters Pisces: Motivation in the Mist & Acting With Compassion22:24 March 3 Lunar Eclipse in Virgo: Pisces vs Virgo, Discernment, and Jupiter Release Valve27:33 Eclipse Family Themes: Looking Up Bernadette Brady's Take28:07 Mercury Retrograde + Eclipse Season Wrap-Up: Slow Down & Communicate29:55 Early March Sweet Spots: Venus–Uranus & Sun–Jupiter Good Vibes31:16 Venus Enters Aries: Passion, Risk-Taking & Relationship Heat32:35 March 7–8 Clarity & Magnetism: Mercury Cazimi + Saturn–Neptune Activation35:24 Transformation & Forward Motion: Venus–Pluto + Jupiter Stations Direct38:24 Fated Action Points: Mars–North Node & Mercury–Mars During Retrograde39:45 March 18–19 Tension, Breakthroughs & Healing Closure (Chiron–Eris)42:58 Astrological New Year Ignition: Sun into Aries + Mercury Direct45:45 Chart Rundown & The Most Aries Day Ever: 7 Planets in Aries (March 20)50:14 Final Takeaways: Choosing the First Step Into Your New IdentityWork with meJournée (membership): Join hereCosmic Consult (1:1): Book here — we'll look at what's being activated in your chart and map the next right stepWhere to find mecosmicmoves.com

Gregory Zuckerman concludes by crediting American finance for enabling these scientific breakthroughs and expressing optimism that mRNA technology will soon tackle cancer and other illnesses. 8

Griff Jenkins reports from Arizona on the ongoing Guthrie murder investigation, detailing how investigative genetic genealogy and trace DNA could finally lead to a breakthrough after 19 days with no suspect. He discusses the local community's reaction, forensic methods, and potential timelines for results. Jenkins also previews Washington D.C.'s upcoming State of the Union, including anticipated protests and congressional attendance, highlighting the intersection of local tragedies, national security concerns, and high-profile political events. Hashtags: #GriffJenkins #GuthrieCase #DNAForensics #InvestigativeGenetics #ArizonaNews #StateOfTheUnion #Congress #Protests #NationalSecurity

Tiffay Hoeft owns Minds Matter in Aberdeen. She joins SDPB's Lori Walsh for a conversation about neurofeedback, mindfulness, and how to reduce your risk for dementia.

Patrick Bet-David sits down with Dr. Rhonda Patrick to break down biological vs. chronological aging, AI-driven gene therapy and stem-cell breakthroughs, creatine and fasting for brain performance, exercise's role in reversing heart aging and lowering cancer risk, GLP-1 weight-loss debates, anxiety hacks, and the science behind longevity, family, and happiness.------

Llion Jones cowrote "Attention Is All You Need," the seminal paper that introduced the transformer — the architecture that launched the generative AI revolution. Now he warns that the industry that grew out of this breakthrough is stifling the next one. Learn why the current corporate arms race is killing true innovation and how we can get back to bold exploration.Learn more about our flagship conference happening this April at attend.ted.com/podcast Hosted on Acast. See acast.com/privacy for more information.

Bodies don't just wear down, they lose communication. What happens when that internal signal starts working again and hundreds of people suddenly experience dramatic turnarounds? I talk with Bobbi Vitality about a new wave of smart medicine, why documented testimonies are multiplying, and how faith and science are intersecting in unexpected ways. You'll come away seeing your body less as fragile and more as designed with restoration already built inside it.   Podcast Episode 2025: Smart Medicine Breakthroughs + 700 Recovery and Healing Testimonies | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast

God surely has reasons for waiting to give you the breakthrough you have sought for decades. Keep asking in hope.